901 Treatment of Interstitial Cystitis With Botulinum Toxin Type A

Carl, S.; Grosse, J.; Laschke, S.

doi:10.1016/s1569-9056(07)60896-3

Cited by 5 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, the therapeutic results were disappointing because no favorable evolution was observed after three months of treatment. Carl et al conducted a pilot study involving 29 patients with painful bladder syndrome and injected them with BoNT-A, to demonstrate that it is useful in the treatment of this pathology [ 97 ]. The toxin was injected submucosally, into the trigonal area, and the results contrary to those obtained by Kuo et al [ 96 ], suggested that BoNT-A has an antinociceptive effect on the bladder afferent nerves in patients with chronic interstitial cystitis.…”

Section: Review Of the Literature Regarding The Gynecologic Indicamentioning

confidence: 99%

Therapeutic Approaches of Botulinum Toxin in Gynecology

Moga

Dimienescu

Bălan

et al. 2018

Toxins

View full text Add to dashboard Cite

Botulinum toxins (BoNTs) are produced by several anaerobic species of the genus Clostridium and, although they were originally considered lethal toxins, today they find their usefulness in the treatment of a wide range of pathologies in various medical specialties. Botulinum neurotoxin has been identified in seven different isoforms (BoNT-A, BoNT-B, BoNT-C, BoNT-D, BoNT-E, BoNT-F, and BoNT-G). Neurotoxigenic Clostridia can produce more than 40 different BoNT subtypes and, recently, a new BoNT serotype (BoNT-X) has been reported in some studies. BoNT-X has not been shown to actually be an active neurotoxin despite its catalytically active LC, so it should be described as a putative eighth serotype. The mechanism of action of the serotypes is similar: they inhibit the release of acetylcholine from the nerve endings but their therapeutically potency varies. Botulinum toxin type A (BoNT-A) is the most studied serotype for therapeutic purposes. Regarding the gynecological pathology, a series of studies based on the efficiency of its use in the treatment of refractory myofascial pelvic pain, vaginism, dyspareunia, vulvodynia and overactive bladder or urinary incontinence have been reported. The current study is a review of the literature regarding the efficiency of BoNT-A in the gynecological pathology and on the long and short-term effects of its administration.

show abstract

Section: Review Of the Literature Regarding The Gynecologic Indicamentioning

confidence: 99%

Therapeutic Approaches of Botulinum Toxin in Gynecology

Moga

Dimienescu

Bălan

et al. 2018

Toxins

View full text Add to dashboard Cite

show abstract

“…Cependant, aucune d'entre elles ne rapporte de disparition complète des symptômes [18][19][20][21][22][23].…”

Section: Résultatsunclassified

Y-a-t-il une place pour un traitement de la cystite interstitielle par toxine botulique A ? Revue de la littérature

et al. 2009

View full text Add to dashboard Cite

La toxine botulique de type A (TBA) aurait un rôle dans la modulation du message douloureux par son action sur la voie afférente vésicale. Cette nouvelle approche a conduit à utiliser la TBA contre la douleur et l'urgenturie chez les patients atteints de syndrome de vessie douloureuse-cystite interstitielle. Objectif : Évaluer l'intérêt de l'utilisation de la TBA dans le traitement du syndrome de vessie douloureuse-cystite interstitielle par une revue de la littérature. Méthode : Une recherche d'études cliniques a été réalisée grâce au moteur de recherche Pubmed en utilisant botulinum toxin et interstitial cystitis comme mots clés, et les résultats ont été analysés. Résultats : Onze études cliniques ont été répertoriées (252 patients). Neuf articles ont montré une amélioration significative sur les symptômes, mais aucun patient n'a été asymptomatique. Six articles ont étudié les troubles de la vidange vésicale après injection de TBA : 20 à 63 % des patients étaient dysuriques, conduisant 12,5 % d'entre eux à la réalisation d'autosondages. Deux études n'ont pas retrouvé d'amélioration clinique après injection, excepté pour un patient qui était asymptomatique. Discussion : La majorité de ces études conclut à une efficacité de la TBA dans le traitement du syndrome de vessie douloureuse-cystite interstitielle malgré le faible nombre de patients asymptomatiques après injection (un sur 252 patients). Dix sur 11 de ces articles ont un faible niveau de preuve scientifique, et les résultats ont été exploités de façon différente, rendant les comparaisons difficilement objectives : durée de l'effet de l'injection de TBA, troubles de la vidange, alors qu'il est établi que la dysurie et la rétention augmentent la douleur dans cette pathologie.Conclusion : La TBA ne devrait pas être utilisée comme traitement du syndrome de vessie douloureuse-cystite interstitielle, excepté dans le contexte d'essai contrôlé randomisé. Mots clés Cystite interstitielle · Syndrome de vessie douloureuse · Toxine botulique AAbstract Background: Botulinum toxin appears to have a role in the genesis of nociceptive messages through its effect on afferent pathways. This new approach is behind the use of BTA to treat pain and frequency problems for patients with bladder pain syndrome-interstitial cystitis (BPS-IC). AIM: To assess the value of using BTA in the treatment of BPS-IC, through a literature review. Method: A Medline search for clinical studies with botulinum toxin and interstitial cystitis was carried out, extracted data were reviewed and analysed. Results: Eleven clinical studies were found (252 patients). Nine articles showed significant improvement of symptoms but no patient was symptom free. Six studies evaluated voiding dysfunction after BTA injection: dysuria-retention affected 20 to 63% of whom 12.5% resorted to self catheterisation. The two remaining studies had disappointing results: no clinical improvement with TBA except for one patient who was symptom free. Discussion: Most of these articles conclude that BTA is effective, despite o...

show abstract

“…53 Evidence level 1-A systematic review 54 evaluating intravesical injection of Botox in BPS patients found three RCTs [55][56][57] and seven prospective cohort studies [58][59][60][61][62][63][64] with a total of 260 patients. Eight of these studies reported symptomatic improvement, 55,56,[58][59][60][61]63,64 although, 7% of patients needed post-treatment selfcatheterisation. Clinicians and patients might consider trying bladder instillations before resorting to invasive treatments like Botox injections into the bladder, including the trigone.…”

mentioning

confidence: 99%

Management of Bladder Pain Syndrome

2016

BJOG

View full text Add to dashboard Cite

901 Treatment of Interstitial Cystitis With Botulinum Toxin Type A

Cited by 5 publications

References 0 publications

Therapeutic Approaches of Botulinum Toxin in Gynecology

Therapeutic Approaches of Botulinum Toxin in Gynecology

Y-a-t-il une place pour un traitement de la cystite interstitielle par toxine botulique A ? Revue de la littérature

Management of Bladder Pain Syndrome

Contact Info

Product

Resources

About